Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.

ESMO Open · 2023 · PMC10774956 · PMID 37988950

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

3 , 32 , 33 Furthermore, nivolumab plus chemotherapy showed a trend toward providing OS benefit in either high or low TMB subgroups, similar to other studies. 12 , 19 Our results showed prolonged survival in patients with a LIPI score of 0 (good) compared with a LIPI score of 1 or 2 (intermediate or poor, respectively) and demonstrated the potential prognostic valu

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.